GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/03/21
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021Business Wire • 05/03/21
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma ModelBusiness Wire • 04/10/21
Positive Findings From Phase 1b Trial of GlycoMimetics' GMI-1359 To Be Presented at AACR 2021 MeetingBusiness Wire • 04/10/21
GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 MeetingBusiness Wire • 03/10/21
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AMLBusiness Wire • 03/04/21
GlycoMimetics, Inc.'s (GLYC) CEO Rachel King on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020Business Wire • 03/02/21
GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor ConferencesBusiness Wire • 02/26/21
GlycoMimetics to Report Fourth Quarter and Year-End 2020 Financial Results on March 2Business Wire • 02/23/21
New Supportive Efficacy Data for GlycoMimetics' Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and ExpositionBusiness Wire • 12/07/20
GlycoMimetics' Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML ModelBusiness Wire • 12/05/20
GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor ConferencesBusiness Wire • 11/10/20
GlycoMimetics' (GLYC) CEO Rachel King on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2020Business Wire • 11/06/20
GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and ExpositionBusiness Wire • 11/04/20
New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 RESET Trial Presented at The Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) MeetingBusiness Wire • 10/26/20
FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell DiseaseBusiness Wire • 10/05/20